Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Correlation between genetic heterogeneity and variability for response to growth hormone in Noonan syndrome

  • Shin, Young-Lim (Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine)
  • Received : 2019.03.04
  • Accepted : 2019.07.02
  • Published : 2019.11.15
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013;381:333-42. https://doi.org/10.1016/S0140-6736(12)61023-X
  2. Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics 2010;126:746-59. https://doi.org/10.1542/peds.2009-3207
  3. Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR. Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr 1988;148:220-7. https://doi.org/10.1007/BF00441408
  4. Noonan JA, Kappelgaard AM. The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence. Horm Res Paediatr 2015;83:157-66. https://doi.org/10.1159/000369012
  5. Tajan M, Paccoud R, Branka S, Edouard T, Yart A. The RASopathy Family: consequences of germline activation of the RAS/MAPK Pathway. Endocr Rev 2018;39:676-700. https://doi.org/10.1210/er.2017-00232
  6. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007;39:75-9. https://doi.org/10.1038/ng1939
  7. El Bouchikhi I, Belhassan K, Moufid FZ, Iraqui Houssaini M, Bouguenouch L, Samri I, et al. Noonan syndrome-causing genes: molecular update and an assessment of the mutation rate. Int J Pediatr Adolesc Med 2016;3:133-42. https://doi.org/10.1016/j.ijpam.2016.06.003
  8. Binder G, Neuer K, Ranke MB, Wittekindt NE. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 2005;90:5377-81. https://doi.org/10.1210/jc.2005-0995
  9. Choi JH, Lee BH, Jung CW, Kim YM, Jin HY, Kim JM, et al. Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation. Horm Res Paediatr 2012;77:388-93. https://doi.org/10.1159/000339677
  10. Tamburrino F, Gibertoni D, Rossi C, Scarano E, Perri A, Montanari F, et al. Response to long-term growth hormone therapy in patients affected by RASopathies and growth hormone deficiency: Patterns of growth, puberty and final height data. Am J Med Genet A 2015; 167A:2786-94.
  11. Binder G. Noonan syndrome, the Ras-MAPK signalling pathway and short stature. Horm Res 2009;71 Suppl 2:64-70.
  12. Jo KJ, Kim YM, Yoon JY, Lee YJ, Han YM, Yoo HW, et al. Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with Noonan syndrome. Korean J Pediatr 2019;62:274-80. https://doi.org/10.3345/kjp.2018.06842
  13. Noordam C, Peer PG, Francois I, De Schepper J, van den Burgt I, Otten BJ. Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11. Eur J Endocrinol 2008;159:203-8. https://doi.org/10.1530/EJE-08-0413